Strategies for innovation in the modern pharmaceutical landscape

This whitepaper explores the critical pressures facing the pharmaceutical industry, specifically the “patent cliff” where many high-selling biologic drugs are losing exclusivity. As blockbuster brands expire, originator companies are struggling to compete with cheaper biosimilar alternatives while simultaneously facing slower R&D pipelines. This challenge is compounded by the rising costs and extended timelines required to bring new, innovative drugs to market.

To remain competitive, the report highlights that pharmaceutical companies are pivoting toward more agile and collaborative business models. Key trends include the consolidation of companies to pool resources and a significant increase in strategic R&D partnerships. By adopting these new pathways to drug discovery and reinvesting in diverse innovation routes, firms aim to replenish their pipelines and adapt to an increasingly complex global healthcare environment.